Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2014-05-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Omega-3 Supplementation After Surgical Treatment of Obesity
NCT06494566
Effects of N-3 Intake on Lipid Profile, Biochemical and Inflammatory Markers in Subjects with Obesity
NCT04901052
n-3 Polyunsaturated Fatty Acids in Obesity
NCT00760760
Omega-3 Fatty Acid Supplementation in Older Adults
NCT01666392
Metabolic Actions of Omega-3 Fatty Acids
NCT01896414
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
\- Reduction of inflammatory factors such as adipokines, glucose, C-reactive protein, cholesterol, weight, BMI. Will be 2 groups: cases and controls. The cases will intake of omega 3 capsules and placebo control.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo group
Placebo Capsules
Placebo Capsules
They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
Omega 3 intake
Omega 3 intake, morbid obesity
Omega 3 intake, morbid obesity
Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Omega 3 intake, morbid obesity
Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
Placebo Capsules
They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \> 40 kg/m2 (or \> 35 kg/m2 with comorbidities),
* ambulatory, receiving an oral diet,
* with a diagnosis of metabolic syndrome,
* and who signed a Term of Free and Informed Consent.
Exclusion Criteria
* coma or compromised organ,
* fever or infection foci,
* cancer with or without chemotherapy and radiotherapy,
* radiotherapy, inflammatory diseases of the gastrointestinal tract,
* transplant, trauma, surgery or hospital stay in the past 30 days
* use of steroids or non-steroid anti-inflammatory or immunomodulators agents or antibiotics,
* or those refusing to take part in the study.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pontificia Universidade Católica do Rio Grande do Sul
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudio C Motin, orientador
Role: STUDY_DIRECTOR
Centro de Obesidade Mórbida da Pontificia Universidade Católica do RS
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
primary
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.